Clinical Resources for Clinicians · For clinicians
Sickle Cell Disease in Pregnancy: A Co-Management Framework
Pregnancy in sickle cell disease is high-risk for both mother and fetus and calls for joint MFM and hematology care from preconception through postpartum. The core elements: a preconception medication review (hydroxyurea above all), partner hemoglobinopathy testing, folic acid, low-dose aspirin, close surveillance for preeclampsia and fetal growth, a written crisis plan, a selective approach to transfusion, and attention to VTE risk.
Why shared care, and why early
Sickle cell disease (HbSS, HbSC, HbS-β-thalassemia and others) carries higher rates of:
- Maternal complications: vaso-occlusive pain episodes, which often become more frequent in pregnancy; acute chest syndrome; infection, especially urinary and pulmonary; VTE; preeclampsia; and maternal death
- Fetal and neonatal complications: fetal growth restriction, preterm birth and stillbirth
HbSC is the genotype most often underestimated. Baseline hemoglobin is higher and patients may look well, but serious complications still occur. In New York, sickle cell disease is common enough that most obstetric practices will care for affected patients. These pregnancies are generally best delivered at a center with MFM, hematology, a blood bank able to provide extended phenotype matching, and critical care, which in practice often means one of the state's Regional Perinatal Centers. Plan the delivery site early rather than at 36 weeks.
Preconception checklist
| Element | Detail |
|---|---|
| Hematology review | Baseline Hb, transfusion history, alloantibodies, iron status, end-organ assessment |
| Medication review | Hydroxyurea (see below); ACE inhibitors/ARBs stopped; review iron chelators and disease-modifying agents |
| Partner testing | Hemoglobinopathy screening of the partner; genetic counseling if both carry a significant variant |
| Folic acid | Supplement before conception; many guidelines advise a higher dose in SCD |
| Vaccinations | Review pneumococcal, meningococcal, influenza, COVID-19 and hepatitis B status |
| End-organ screening | Renal function, proteinuria, echocardiography as indicated, retinal exam |
| Alloimmunization record | Ensure the blood bank has antibody history and extended phenotype |
The realistic problem is that many patients arrive already pregnant. When that happens, compress this list into the first visit or two rather than skipping it.
Hydroxyurea
Hydroxyurea is teratogenic in animal studies. Traditional guidance, including the RCOG approach, has been to stop it before conception or as soon as pregnancy is recognized. Human exposure data are reassuring but limited, and some experts now individualize the decision for patients with severe disease. Make the call with hematology before conception if possible, and decide what replaces hydroxyurea's protective effect, which may include a transfusion program. It's generally avoided during breastfeeding, though that too is being re-evaluated.
Newer disease-modifying agents have very limited pregnancy data. Review each with hematology.
Antenatal care in practice
Visit cadence and labs
- Frequent visits, often every 2–4 weeks early and more often later, alternating or combined between MFM and hematology
- CBC and reticulocyte count at most visits, plus periodic renal and liver function
- Urine culture each trimester or more often, since asymptomatic bacteriuria is common and pyelonephritis can trigger crises
- Blood pressure and proteinuria monitoring for preeclampsia
Preeclampsia prevention
Many patients with SCD meet USPSTF and ACOG criteria for low-dose aspirin based on combined risk factors. RCOG recommends low-dose aspirin from 12 weeks for all pregnant patients with SCD, and most US MFM practices offer it.
Fetal surveillance
Serial growth ultrasounds from the late second trimester, with antenatal testing as indicated. Fetal growth restriction is a recognized complication.
Iron and folate
- No empiric iron. Check ferritin. Patients with a transfusion history may be iron-overloaded, though true iron deficiency also occurs and should be treated when documented. See interpreting iron studies.
- Continue folic acid throughout.
Acute pain and acute chest syndrome
Every patient should have a written individualized crisis plan that L&D and the ED can see, ideally in the shared record and in the patient's phone. Principles:
- Rapid analgesia within NHLBI-recommended time frames. Opioids are appropriate and shouldn't be withheld because of pregnancy. Avoid NSAIDs after about 20 weeks, and especially in the third trimester, because of fetal ductal and renal effects.
- Hydration, avoiding fluid overload, particularly with preeclampsia
- Incentive spirometry to reduce acute chest syndrome risk
- A low threshold to evaluate for acute chest syndrome: new infiltrate, hypoxia, chest pain or fever. Treat with antibiotics, oxygen and early hematology involvement for transfusion or exchange.
- VTE prophylaxis during admission
- Fetal assessment appropriate to gestational age
Transfusion
| Approach | Use |
|---|---|
| Acute simple or exchange transfusion | Acute chest syndrome, severe acute anemia, stroke, multi-organ failure, preoperative per hematology |
| Prophylactic transfusion program | Selected patients: prior severe complications, worsening crises, multiple gestation, or those previously on hydroxyurea; individualized |
| Routine prophylactic transfusion for all | Not recommended by ACOG or RCOG |
Alloimmunization is common in SCD and can make finding compatible blood harder, now and in later pregnancies. ASH 2020 transfusion guidance recommends extended red cell antigen matching (at least Rh C, E and K) for patients with SCD. Alert the blood bank early and send a type and screen at intervals. If the patient has been transfused at another hospital, chase that antibody history; it's frequently missing.
VTE
SCD is an independent VTE risk factor in pregnancy. Consider antenatal prophylaxis during admissions and individualized postpartum prophylaxis per ACOG PB 196 and institutional risk scoring. See thrombophilia testing and VTE prophylaxis.
Delivery
- Plan delivery at a center with appropriate support. Timing is individualized; RCOG suggests offering planned birth at about 38–40 weeks in uncomplicated cases.
- Cesarean for obstetric indications only.
- Intrapartum: keep the patient warm, oxygenated and hydrated, and avoid prolonged labor. Encourage neuraxial analgesia, since good pain control lowers crisis risk.
- Have crossmatched blood available and involve anesthesia early.
Postpartum
- Crises and acute chest syndrome remain common early postpartum. Monitor closely, and don't discharge without a clear plan for who the patient calls.
- Thromboprophylaxis per risk assessment.
- Contraception: progestin-only methods and the LNG-IUD are generally appropriate under the CDC MEC. Estrogen-containing methods are category 2 for SCD, though other VTE risk factors may change that. Discuss interpregnancy interval.
- Plan the timing of resuming hydroxyurea or other disease-modifying therapy with hematology.
- The newborn needs pediatric follow-up based on parental genotypes, and New York's newborn screening program tests for sickle cell disease.
The relational piece
Many patients with SCD have experienced undertreated pain or stigma in emergency settings, and that history can make them reluctant to come in during a crisis. What helps: a clear written plan, continuity of clinicians, and saying explicitly that pain will be treated promptly. Screen for depression and anxiety in pregnancy and postpartum, and connect patients with social work and community sickle cell organizations where available.
Trait and other hemoglobinopathies
Sickle cell trait (HbAS) is not sickle cell disease, and most carriers have uncomplicated pregnancies. ACOG notes a possible increase in urinary tract infection risk; the main clinical importance is partner testing and genetic counseling. Don't apply SCD protocols to patients with trait.
Other hemoglobinopathies, such as beta-thalassemia intermedia or HbH disease, also need hematology input, with attention to iron overload, transfusion needs and VTE risk. Partner screening and genetic counseling apply here too.
Referral partnership in New York
SCD in pregnancy is a clear case for shared care from preconception onward. Premier Hematology & Oncology, which sponsors our professional resources, offers referral pathways and co-management for hemoglobinopathies in pregnancy, along with fast-track IV iron scheduling when iron deficiency is documented. See our hematology partners page and our hematology referral checklist. To find MFM colleagues, browse maternal-fetal medicine in the Bronx.
Frequently asked questions
Is sickle cell disease in pregnancy high risk?
Yes. Pregnancy in sickle cell disease carries higher risks of pain crises, acute chest syndrome, VTE, preeclampsia, fetal growth restriction, preterm birth and maternal mortality. It should be managed by MFM and hematology together.
Should hydroxyurea be stopped in pregnancy?
Hydroxyurea has traditionally been stopped before conception or when pregnancy is recognized, because of teratogenicity concerns from animal data. Decisions are increasingly individualized, so involve hematology before conception.
Should pregnant patients with sickle cell disease get iron?
Only if iron deficiency is documented. Many patients with sickle cell disease, especially those who have been transfused, have normal or high iron stores, so check ferritin before supplementing.
Are routine prophylactic transfusions recommended in sickle cell pregnancy?
Not for all patients. Transfusion is used for specific indications, and prophylactic programs are considered for selected high-risk patients after weighing the risk of alloimmunization.
Sources
- ACOG — Hemoglobinopathies in Pregnancy (Practice Bulletin No. 78)
- RCOG — Management of Sickle Cell Disease in Pregnancy (Green-top Guideline No. 61)
- ASH — 2020 guidelines for sickle cell disease: transfusion support
- NHLBI — Evidence-Based Management of Sickle Cell Disease: Expert Panel Report (2014)
- USPSTF — Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality (2021)
- ACOG — Thromboembolism in Pregnancy (Practice Bulletin No. 196)
This article is for general education and is not medical advice. It does not replace an evaluation by a licensed clinician who knows your history. If you think you have a medical emergency, call 911.